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Summary Percutaneous mitral valve commissurotomy (PMC) is the treatment of choice for
patients with mitral stenosis (MS) and favorable anatomy. Evaluation of MS should answer two
questions: is MS severe? And is the valve suitable for PMC?
Evaluation of MS severity relies on accurate echocardiographic assessment of the mitral valve
area (MVA). Several methods can be used, often in combination. The planimetry is the reference
method but must be precisely performed at the tips of the leaﬂets in a well-oriented plane and
thus requires experienced operators. New imaging technologies, such as 3D-echocardiography,
MRI or computed tomography may reduce planimetry’s operator dependence. The pressure half-
time method (PHT) has the merit of simplicity but should be used cautiously in elderly patients
or those in atrial ﬁbrillation. It is invalid immediately after PMC but can still be used as a semi-
quantitative method: a PHT less than 130 msec is associated with a good valve opening with
an excellent speciﬁcity and positive predictive value whereas a PHT 130msec does not allow
any conclusion. The continuity equation, easy to perform, may be invalidated by the commonly
associated aortic or mitral regurgitation or in case of atrial ﬁbrillation. The PISA method, is
reputed technically challenging and requires a direct measurement of angle between the mitral
leaﬂets, although the use of a ﬁxed value of 100◦ provides an accurate MVA estimation. The
main indication of transesophageal echocardiography is the exclusion of left atrial thrombus,
which is a contra-indication to PMC as well as a 2/4 or greater mitral regurgitation grade.
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into account not only the valve anatomy but also individual patients characteristics such as
age, rhythm, NYHA class, MVA and the predicted operative mortality based on associated
MOTS CLÉS
Sténose mitrale ;
Échocardiographie ;
Scanner ;
Évaluation
valvulaire mais également l’âge, le rythme, la classe fonctionnelle New York Heart Association,
la surface et la mortalité opératoire estimée selon des scores de risque reposant principalement
es.
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bbreviations
T Computed tomography
VOT Left ventricular outﬂow tract
RI Magnetic resonance imaging
SCT Multi-slices computed tomography
S Mitral stenosis
VA Mitral valve area
YHA Mew York Heart Association
HT Pressure half-time
ISA Proximal isovelocity surface area
MC Percutaneous mitral valve commissurotomy
-D Three-dimensional
VI Time-velocity integral
-D Two-dimensional
o
m
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ntroduction
he principal cause of MS is rheumatic heart disease. Despite
striking decrease in the prevalence of rheumatic fever,
S remains a signiﬁcant problem in Western countries,
ccounting for 12% of native valvular heart disease, par-
ially due to immigration from developing countries [1].
he clinical presentation of MS has changed, however;
owadays, it tends to affect older patients with mitral
alve calciﬁcation. In developing countries, rheumatic fever
emains endemic, and MS is a major public health prob-
em.D. Messika-Zeitoun et al.
Two-dimensional-echocardiography allows detailed evaluation of valve morphology, including
leaﬂet thickness and mobility, degree and localization of calciﬁcations, extent of the subvalvu-
lar involvement. Unfavorable valve anatomy is associated with a lower rate of PMC success
and lower event-free survival. However, given the low predictive value of all anatomic scores,
the decision to perform or not the procedure should be based on a global approach takingcomorbidities.
© 2008 Elsevier Masson SAS. All rights reserved.
Résumé La commissurotomie mitrale percutanée (CMP) est le traitement de première
intention de la sténose mitrale (rétrécissement mitral [RM]) lorsque l’anatomie valvulaire
le permet. Lors de l’évaluation d’un patient présentant un RM deux points doivent être
précisés : (1) est-ce que la sténose mitrale est sévère, (2) une CMP est-elle envisageable ?
L’évaluation de la sévérité du RM repose sur la mesure de la surface valvulaire mitrale
(MVA). Plusieurs méthodes sont possibles et doivent souvent être effectuées conjointe-
ment. La planimétrie est la méthode de référence, mais doit être effectuée précisément au
sommet de l’entonnoir mitral et nécessite un opérateur expérimenté. Les nouvelles modal-
ités d’imagerie, comme l’échographie tridimensionnelle ou le scanner, sont intéressantes
et semblent moins operateurs-dépendantes. Le temps de demi-pression, ou PHT, est une
méthode simple, mais pas toujours ﬁable en particulier chez les sujets âgés ou en cas de
ﬁbrillation auriculaire. Elle n’est pas valide immédiatement après CMP, mais un temps de
demi-pression court (< 130millisecondes) est associé à un bon résultat de CMP avec une
excellente valeur prédictive positive alors qu’un temps 130millisecondes n’est pas inter-
prétable. L’équation de continuité est relativement simple mais invalide en cas de fuite
aortique ou mitrale associée et en cas de ﬁbrillation auriculaire. La proximal isovelocity
surface area est réputée complexe et nécessite une correction d’angle (mesure de l’angle
formé par les feuillets valvulaire). Toutefois, l’utilisation d’une valeur ﬁxe de 100◦ four-
nit une approximation acceptable en pratique clinique. L’échographie transœsophagienne est
essentiellement utile pour éliminer un thrombus auriculaire qui est une contre-indication (tem-
poraire) à la CMP. Une fuite de grade supérieur ou égale à 2/4 contre-indique également
la procédure. L’échographie bidimensionnelle permet une évaluation détaillée et précise de
l’anatomie valvulaire et de l’appareil sous-valvulaire, en particulier l’épaisseur et la mobil-
ité des feuillets et le degré et la localisation d’éventuelles calciﬁcations. Une anatomie
défavorable est associée à un moins bon résultat immédiat et à long terme de la CMP. Toute-
fois, au vue de la modeste valeur prédictive des différents scores anatomiques, la décision
d’effectuer ou non la CMP doit se fonder sur une approche globale prenant en compte l’anatomieIn contrast to other valvular disease (with the exception
f aortic stenosis, for which percutaneous valve replace-
ent is an emerging option), surgery is not the only
reatment strategy for MS. Since its introduction by Inoue
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et al. in 1984 [2], PMC has been performed successfully and
safely in large series of patients at numerous centres [3—7],
and has emerged as the treatment of choice for patients with
MS and a favourable anatomy [8,9]. Nowadays, echocardio-
graphy plays a key role in the assessment of MS severity and
anatomy, and catheterization is used only rarely. The eval-
uation of MS should answer two questions: is the MS severe
and is the valve suitable for PMC? In this review, we discuss
the evaluation of patients with MS in 2008, underlining the
potential role of new technologies such as CT, MRI and 3-D
echocardiography.
Evaluation of MS severity
The management of patients with MS relies on the accurate
assessment of MS severity. MVA is the main criterion, with
clinically-signiﬁcant MS deﬁned as an MVA less or equal
to 1.5 cm2 [9]. In some patients, it may be useful to take
body size into account; there is general agreement that
MS is signiﬁcant if the MVA is less than 0.9 or 1 cm2/m2
of body surface area. The mean transmitral gradient,
determined from the transmitral velocity curve, is less
useful because of its dependence on heart rate, rhythm and
cardiac output, but it can still be regarded as an indicator
and is an important prognostic factor. As cardiac catheter-
ization is used typically to perform PMC, MVA is most often
measured non-invasively by Doppler echocardiography, for
clinical decision-making. Four different methods can be
used: planimetry, PHT, continuity equation and PISA. Each
method has its speciﬁc limitations. We use planimetry
preferentially in our clinical practice, but a combination of
methods is recommended for less experienced operators or
in difﬁcult clinical situations, to improve the consistency
and reliability of MVA measurements.
Planimetry
Planimetry provides an anatomical measurement of the
mitral valve oriﬁce; it is considered to be the reference
method and correlates closely with anatomical ﬁndings
[10,11]. Planimetry is performed in parasternal short-axis
view, precisely at the tips of the leaﬂet in a well-orientated
plane (Fig. 1). The procedure requires an experienced
operator because minor changes to the depth or angle
of the ultrasound beam may lead to signiﬁcant MVA
overestimation [12]. To avoid such overestimation, it is
important to scan slowly from the apex to the base and
to select the narrowest oriﬁce. Planimetry may not be
feasible in approximately 5% of patients because of a
poor echocardiographic window or massive calciﬁcations
[6]. Because of these limitations, other technologies have
been evaluated, namely 3-D echocardiography, CT and
MRI.
3-D echocardiography is a relatively recent imaging tech-
nique that permits the 3-D visualization of heart structures.
With improvement of transducer technology (matrix array
transducer), on-line 3-D acquisition, visualisation and anal-
ysis have become possible (real-time 3-D transthoracic
echocardiography). The process allows the 3-D acquisition
of the entire mitral valve, which can be sliced along any
plane as desired, and thus overcomes a major limitation
t
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f 2-D echocardiography (Fig. 2) [13]. A recent study has
hown that 3-D echocardiography provides better reliability
han 2-D echocardiography among inexperienced operators
level I training in echocardiography) (Fig. 3), reﬂecting its
reater accuracy in providing the image plane with the true
riﬁce of the mitral valve [14]. This should be considered as
potential indication for 3-D echocardiography.
MSCT also enables the 3-D acquisition of the entire heart
hroughout the cardiac cycle and multiple plane recon-
tructions; like echocardiography, therefore, it can provide
parasternal short-axis view of the mitral valve oriﬁce
t the tips of the leaﬂet in early diastole (Fig. 4). We
howed recently that accurate and reproducible planime-
ry of the mitral valve oriﬁce could be achieved using a
6-detector-row scanner with commercially-available car-
iac reconstruction software and contrast enhancement
15]. MSCT measurements correlated well with, and did
ot differ from, echocardiographic measurements; themean
ifference was small and intra- and interobserver variabil-
ty were low. In addition, acquisition of CT images depends
n the protocol used, which can be preregistered in the
T system, and a step-by-step operations manual for plane
rientations can then be produced, which may reduce the
perators’ dependence on MSCT measurements. After brief
raining, an inexperienced operator (a radiology technolo-
ist with no previous experience in valvular disease) was
sked to perform the measurements alone, and produced
esults that did not differ from those of experienced opera-
ors. It is worth noting that only patients in sinus rhythm
ere enrolled in this study. MSCT can therefore be con-
idered as an alternative to MVA measurement in patients
ith poor echocardiographic windows or for teams unac-
ustomed to evaluating patients with MS. Because of the
ntrinsic limitations of MSCT (i.e. risk of irradiation and
odine contrast), we do not recommend this procedure as
ﬁrst-intention method for the assessment of MS sever-
ty.
Preliminary results suggest that planimetry of the
itral valve oriﬁce using MRI is feasible and reliable,
espite some degree of overestimation of the MVA [16].
elocity-encoded cardiovascular magnetic resonance may
lso facilitate calculation of the MVA using the PHT method
17].
HT
he PHT is the time interval between the maximum early
iastolic gradient and the point at which the gradient is
alf this maximum value. Since the original report by Hatle
t al., based on only 32 patients [18], the PHT method
as gained widespread acceptance, despite the lack of
arge-scale clinical validation [19,20] and theoretical con-
erns [21]. The main advantage of PHT is its simplicity
MVA = 220/PHT); consequently, it is used widely in clinical
ractice in addition to, or even instead of, planimetry. How-
ver, the important limitations of the PHT method should be
mphasized.Tachycardia and non-linear Doppler velocity curves affect
he accuracy and reliability of PHT measurements [22,23].
he PHT method is also invalidated by severe aortic regurgi-
ation. In addition, a major assumption of the PHT method
s that the rate of pressure decline is only determined by
656 D. Messika-Zeitoun et al.
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Migure 1. Examples of mitral valve anatomy. A. Thick valve witho
lexible mitral valve in parasternal long-axis view. D. Calciﬁcation l
estenosis due to valvular rigidity with persistent commissural open
he valve area (and not by the left atrial and ventricu-
ar compliance). In clinical practice, correlation between
lanimetry and PHT is only fair, with discrepancies greater
han or equal to 0.3 cm2 observed in 20% of patients [24].
he PHT method should be used with caution, especially
n older patients or those in atrial ﬁbrillation in whom the
HT may be highly variable from beat to beat. This limita-
ion is of critical importance in Western countries where the
ean age of patients with MS is almost twice that observed
n developing countries, and where one third to one half
f patients with MS are in atrial ﬁbrillation. Furthermore,
ecause of acute atrioventricular compliance changes, the
HT method is reputed invalid immediately after PMC [21].
n our experience, the PHT method does not provide an
ccurate evaluation of the MVA after PMC: the correlation
ith planimetry is weak, the mean difference is large and
discrepancy greater than or equal to 0.3 cm2 is noted
n almost 50% of patients [24]. However, it can still be
t
T
i
o
alciﬁcation. B. Planimetry of MVA in parasternal short-axis view. C.
zed at the level of the medial commissures (small red arrow). E—F.
large arrows).
sed as a semiquantitative method and provides an addi-
ional tool for the evaluation of MVA after PMC in difﬁcult
ases. A PHT less than 130ms is associated with a good
alve opening (MVA≥ 1.5 cm2) with excellent speciﬁcity and
positive predictive value, whereas a PHT greater than
r equal to 130ms does not enable any conclusions to be
rawn.
ontinuity equation
he continuity equation is based on the conservation of
lood ﬂow across the LVOT and the mitral valve (Fig. 5). The
VA is calculated as the ratio of the aortic stroke volume
o the mitral TVI obtained by continuous-wave Doppler.
he continuity equation is quite simple to calculate but
s invalidated by aortic or mitral regurgitation, which are
ften associated with MS [11]. In addition, as mitral and
ortic stroke volumes are calculated from different beats,
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hy. T
at thFigure 2. Measurement of MVA using real-time 3-D echocardiograp
and orientated to obtain the ideal cross-section of the mitral valvethe continuity equation should be used cautiously in cases
of atrial ﬁbrillation; the results from 5—10 beats must
be averaged. Overall, the continuity equation provides
smaller measurements than planimetry, especially after
PMC (functional versus anatomical oriﬁce area).
P
T
[
a
Figure 3. Bland—Altman analysis shows better agreement between (B
2-D planimetry measured by the experienced operator than between (A
operators.he 3-D volume (D), acquired in parasternal short-axis view, is sliced
e tips of the leaﬂets (A—C).ISA
he PISA method is based on the continuity principle
25] and assumes that blood ﬂow converging towards
ﬂat oriﬁce forms hemispheric isovelocity shells. The
) 3-D planimetry measured by the less experienced operator and
) 2-D planimetry measured by less experienced and experienced
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Figure 4. Examples of parasternal short-axis views of the mitral valve oriﬁce obtained by MSCT (with contrast injection; white and
black colours are inverted so that images appear similar to echocardiography). A, B. Commissures are fused in the ﬁrst patient. C. Both
commissures are open. D. Only the lateral commissure is open.
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of MVA throughout diastole (Fig. 7) and has shown thatigure 5. Calculation of the MVA (red arrow) using the continuity
quation.
ISA method is used routinely in many echocardiography
aboratories for the quantitative evaluation of valvu-
ar regurgitation [26]. Many studies have validated the
ISA method for the calculation of MVA in patients
ith MS, under a variety of clinical conditions (includ-
ng differing heart rhythms and severities of anatomical
esions, and with associated aortic or mitral regurgita-
ion) [25,27,28], but it is still used rarely in routine
ractice. The PISA method is a useful tool in patients
ith MS because the proximal convergence method can
e visualized easily and it may be the only method avail-
ble. It is reputed to be technically demanding, but
d
t
o
rhis is not the case if the following rules are adhered
o:
zoom on the ﬂow convergence;
upshift the baseline velocity and use an aliasing velocity
of 20—30 cm/s;
measure the radius of the ﬂow convergence region and the
transmitral velocity at the same time in early diastole;
measure the ˛ angle formed by the mitral leaﬂets.
As a result of leaﬂet doming in MS, only a fraction
f a hemisphere crosses the oriﬁce and an angle correc-
ion factor (˛) must be considered (Fig. 6). This angle
annot be obtained using the machine’s built-in software
nd must be measured manually using a protractor. This
ssue may explain, at least partially, why the use of the
ISA method remains limited in MS. However, the angle
hanges only slightly between patients and the use of a
xed angle value of 100◦ can provide an accurate MVA esti-
ation in patients with MS [29]. This simpliﬁcation should
acilitate and extend the use of the PISA as an additional
ethod for the assessment of MS severity in routine prac-
ice.
Colour M-mode PISA allows instantaneous measurementespite marked ﬂow and velocity changes during diastole,
he MVA remains unchanged, irrespective of the severity
f mitral anatomical alterations or the presence of mitral
egurgitation [28].
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method.
Assessing the consequences of MS
Size of left atrium
Left atrial enlargement is caused by chronic pressure
overload. M-mode measurement is simple but inaccurate
because the left atrium does not enlarge symmetrically. In
both mitral regurgitation [30] and MS (personal unpublished
data), the M-mode diameter estimates left atrial volume
imprecisely, with a wide range of error that increases with
left atrial size. Hence left atrial area — or, for better, left
atrial volume — should be used to estimate left atrial size.
r
T
m
[
p
Figure 7. Examples of measurement of the mitral oriﬁce area in MS by
tracing of the proximal ﬂow convergence and continuous-wave Doppler
mid, mid-late and late) were matched at the same time intervals. The M
rate by the corresponding inﬂow velocity.659
nticoagulation is recommended for patients in sinus rhythm
ith a left atrial diameter greater than 50mm [9]. It is evi-
ent that more precise area or volume thresholds are clearly
eeded.
ystolic pulmonary artery pressure
ncreased left atrial pressure results in pulmonary venous
ypertension. A systolic pulmonary artery pressure greater
han 50mmHg at rest is accepted as an indication for
MC [9]. Stress echocardiography (exercise or dobutamine
chocardiography) may be helpful in the management of
symptomatic patients with MS [31,32]. Exercise echocar-
iography can uncover symptoms and reduced functional
apacity. A systolic pulmonary artery pressure greater than
0mmHg on exercise has been proposed as an indication
or PMC [9]. However, prospective studies are mandatory
o validate this threshold and the predictive value of stress
chocardiography with regard to outcome; our preliminary
xperience suggests that a rapid rise in pulmonary artery
ressure may be more informative than the peak pulmonary
rtery pressure.
ize of right-side chambers and degree of
ricuspid regurgitation
he sizes of the right-side chambers of the heart are a
eﬂection of left atrial and pulmonary venous hypertension.
ricuspid regurgitation is often associated with MS and is
ostly functional; it usually decreases or resolves after PMC
33], but severe tricuspid regurgitation is a risk factor for
oor long-term PMC outcome.
the colour M-mode ﬂow convergence method. The colour M-mode
echocardiographic measurement at four phases of diastole (early,
VA at each phase was then calculated by dividing the mitral ﬂow
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Table 1 Anatomical classiﬁcation of the mitral valve:
Wilkins’s score.
Leaﬂet mobility 1. Highly mobile valve with
restriction of only the leaﬂet
tips
2. Middle portion and base of
leaﬂets have reduced mobility
3. Valve leaﬂets move forward
in diastole mainly at the base
4. No or minimal forward
movement of the leaﬂets in
diastole
Valvular thickening 1. Leaﬂets near normal
(4—5mm)
2. Mid-leaﬂet thickening,
marked thickening of the
margins
3. Thickening extends through
the entire leaﬂets (5—8mm)
4. Marked thickening of all
leaﬂet tissue (8—10mm)
Subvalvular thickening 1. Minimal thickening of
chordal structures just below
the valve
2. Thickening of chordae
extending up to one third of
chordal length
3. Thickening extending to the
distal third of the chordae
4. Extensive thickening and
shortening of all chordae
extending down to the
papillary muscle
Valvular calciﬁcation 1. A single area of increased
echo brightness
2. Scattered areas of
brightness conﬁned to leaﬂet
margins
3. Brightness extending into
the mid-portion of leaﬂets
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Table 2 Anatomical classiﬁcation of the mitral valve:
Cormier’s score.
Echocardiographic group Mitral valve anatomy
Group 1 Pliable non-calciﬁed anterior
mitral leaﬂet and mild
subvalvular disease, i.e. thin
chordae≥ 10mm in length
Group 2 Pliable non-calciﬁed anterior
mitral leaﬂet and severe
subvalvular disease, i.e.
thickened chordae < 10mm in
length
Group 3 Calciﬁcation of mitral valve
of any extent, as assessed by
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missural opening (Fig. 1). PMC should not be considered
in the latter case, but can produce satisfactory results in
patients with commissural refusion and favourable anatomy
—particularly in young patients with no or mild calciﬁcation
Table 3 Contraindications to percutaneous valve com-
missurotomy [9].
MVA≥ 1.5 cm2
Left atrial thrombus
Mitral regurgitation that is more than mild (grade≥ 2)
Severe or bicommissural calciﬁcation
Absence of commissural fusion
Severe concomitant aortic valve disease or severe4. Extensive brightness through
most of the leaﬂet tissue
uitability for PMC
itral valve morphology
-D echocardiography allows detailed evaluation of valve
orphology, including leaﬂet thickness and mobility,
egree and localization of calciﬁcations, and the extent
f the subvalvular involvement (Fig. 1). Several scoring
ystems have been proposed. The method used most widely
as developed at the Massachusetts General Hospital
34]: four features (leaﬂet mobility, leaﬂet thickening,
ubvalvular thickening and calciﬁcation) are scored on
1—4 scale and the total score is obtained by adding
ach of the component scores (Table 1). An unfavourable
natomy, deﬁned by a score greater than 8, is associatedﬂuoroscopy, whatever the
subvalvular apparatus
ith a lower rate of immediate PMC success and a lower
vent-free survival rate. However, this scoring system is
omplex and subjective. In our institution, we use Cormier’s
ethod, which is the simplest scoring system (Table 2).
owever, all the proposed systems have a poor predictive
alue and no direct comparisons between systems are
vailable.
The presence and extent of valvular calciﬁcation is
n important prognostic factor for long-term outcome,
lthough a number of other factors (such as age, heart
hythm, NYHA class and valve area [35]) must also be
aken into consideration. Patients should not be denied
MC solely on the basis of an unfavourable anatomy, as
ood immediate and midterm results can be achieved in
atients with unfavourable anatomy —even those with
alvular calciﬁcation [35,36]. It is important to underline
hat none of the scoring systems accounts for the location
f the calciﬁcation, especially relative to the commissures
37,38].
estenosis after previous commissurotomy
estenosis can occur after commissurotomy as a result of
ommissural refusion or valve rigidity with persistent com-combined tricuspid stenosis and tricuspid regurgitation
Concomitant coronary artery disease requiring bypass
surgery
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Figure 8. Assessment of commissural opening using real-time 3-
D echocardiography. Parasternal short-axis view from ventricular
g
a
L
L
i
s
a
T
s
c
s
i
t
c
t
C
A
a
o
s
m
b
P
i
C
t
p
m
b
l
l
r
a
p
v
s
p
b
F
D
I
Rperspective: en face, medial and lateral views of a patient with
complete bilateral commissural opening.
[39,40]. 3-D echocardiography may provide a more accurate
assessment of the degree of commissural opening (Fig. 8)
[14].
Mitral regurgitation
The detection and quantiﬁcation of the degree of mitral
regurgitation has important implications for the choice of
intervention. A mitral regurgitation grade greater than or
equal to 2 is considered to be a contraindication to PMC
(Table 3). However, in patients with borderline mitral regur-661
itation, PMC is more likely to be performed if the valve
natomy is favourable.
eft atrial thrombus
eft atrial thrombi are usually (but not exclusively) located
n the left appendage [41]. The diagnosis relies on tran-
oesophageal echocardiography, which has high sensitivity
nd speciﬁcity for the detection of left atrial thrombus.
his is the major indication for the use of transoe-
ophageal echocardiography, as almost all other variables
an be assessed by transthoracic echocardiography. Tran-
oesophageal echocardiography should only be performed
mmediately before PMC (or surgery). Although an important
hromboembolic risk factor, left atrial dense spontaneous
ontrast (unlike left atrial thrombus) is not a contraindica-
ion to PMC and is a IIa indication in asymptomatic patients.
onclusion
n evaluation of MS should determine if the MS is severe
nd whether the valve is suitable for PMC. Assessment
f MS severity relies on accurate echocardiographic mea-
urement of the MVA. Planimetry remains the reference
ethod, but is operator-dependent; the use of a com-
ination of other methods (PHT, continuity equation and
ISA) is recommended for less experienced operators or
n difﬁcult clinical situations. 3-D echocardiography and
T seem promising and may decrease planimetry’s opera-
or dependence. The PISA method is used rarely in routine
ractice, but ought to be implemented more widely as it
ay be the only method available and can be simpliﬁed
y using a ﬁxed angle value of 100◦ between the valve
eaﬂets. Unfavourable valve anatomy is associated with a
ower rate of PMC success and a lower event-free survival
ate. However, given the low predictive value of the various
natomical scoring systems for PMC outcome, the decision to
erform the procedure should take into account not only the
alve anatomy but also individual patient characteristics,
uch as age, heart rhythm, NYHA class and valve area, and
redicted operative mortality based on associated comor-
idities.
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